---
title: "UVSP: Q2 2026 net income up 18.8% year-over-year, driven by loan growth and margin expansion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293552404.md"
description: "Q2 2026 net income rose 18.8% year-over-year to $23.0 million, with strong loan and deposit growth, improved net interest margin, and higher returns on assets and equity. Results were impacted by a $5.2 million OREO charge and increased noninterest expenses.Original document: Univest Financial Corporation [UVSP] SEC 8-K Current Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T03:16:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293552404.md)
  - [en](https://longbridge.com/en/news/293552404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293552404.md)
generator: "portal-rs"
---

# UVSP: Q2 2026 net income up 18.8% year-over-year, driven by loan growth and margin expansion

Q2 2026 net income rose 18.8% year-over-year to $23.0 million, with strong loan and deposit growth, improved net interest margin, and higher returns on assets and equity. Results were impacted by a $5.2 million OREO charge and increased noninterest expenses.

Original document: Univest Financial Corporation \[UVSP\] SEC 8-K Current Report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [UVSP.US](https://longbridge.com/en/quote/UVSP.US.md)

## Related News & Research

- [YXT.com Group announces private placement of 500,000 ADSs](https://longbridge.com/en/news/296140600.md)
- [Univest Financial Director Michael L. Turner sells 8,000 common shares for $344,280](https://longbridge.com/en/news/295950746.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)
- [BEWI: Q2 2026 delivered double-digit sales and EBITDA growth, with strong performance across all segments](https://longbridge.com/en/news/296303987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**